English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Breast cancer chemotherapy is associated with accelerated aging and potentially increased risk for Alzheimer's disease (AD).    Methods  We calculated the probability of AD diagnosis from brain network and demographic and genetic data obtained from 47 female AD converters and 47 matched healthy controls. We then applied this algorithm to data from 78 breast cancer survivors.    Results  The classifier discriminated between AD and healthy controls with 86% accuracy ( P  < .0001). Chemotherapy‐treated breast cancer survivors demonstrated significantly higher probability of AD compared to healthy controls ( P  < .0001) and chemotherapy‐naïve survivors ( P  = .007), even after stratifying for apolipoprotein e4 genotype. Chemotherapy‐naïve survivors also showed higher AD probability compared to healthy controls ( P  = .014).    Discussion  Chemotherapy‐treated breast cancer survivors who have a particular profile of brain structure may have a higher risk for AD, especially those who are older and have lower cognitive reserve.

Probability of Alzheimer's disease in breast cancer survivors based on gray‐matter structural network efficiency